Clinical trials: Hepatic Neoplasm
Unresectable or Metastatic Hepatocellular Carcinoma (HCC)
MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.
A Phase 1b/2, open-label, randomized study to evaluate MEDI-573 in combination with standard of care in adult subjects with unresectable or metastatic hepatocellular carcinoma (HCC).
- Trial name
- MEDI-573-1028 (NCT01498952)
- Testing
- MEDI-573 (1 of 3 doses), Sorafenib
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- MedImmune LLC
Rupture, Spontaneous
A New Prognostic Scoring System for Spontaneous Ruptured Hepatocellular
Develop a new scoring system for HCC patients with tumor rupture.
- Trial name
- NCT03504358
- Testing
- Liver resection
- Volunteers
- 129 people
- Sponsor
- Huazhong University of Science and Technology
Hepatitis, Liver Cirrhosis
Evaluation the Growth Factors(IGF-1,IGFBP-3and HGH)in Patients With Chronic Liver Disease
BACKGROUND The insulin-like growth factor system (IGFs) plays an important role in cell growth and differentiation. Nevertheless, the roles played by insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding…
- Conditions
- Hepatitis, Liver Cirrhosis, Hepatocellular Carcinoma
- Trial name
- NCT00679692
- Where
- Taiwan
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Carcinoma, Hepatocellular, Neuroendocrine Tumors
Circulating Tumor Cells and Tumor DNA in HCC and NET
Background Treatment and control of cancer is associated with high costs, to patients in the form of side effects and discomfort during investigations, to society in the form of expensive drugs and studies.
- Trial name
- NCT02973204
- Testing
- Sorafenib, Radiofrequency ablation (RFA) or surgery, Everolimus
- Where
- Denmark
- Volunteers
- 167 people
- Sponsor
- University of Aarhus
Hepatocellular Carcinoma (HCC)
A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence
This study aims to compare the safety and tolerability of cadonilimab applied after curative hepatectomy for hepatocellular carcinoma combined with high - risk recurrent factors.
- Trial name
- NCT06851104
- Testing
- Cadonilimab (AK104)
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Parathyroid Diseases, Thyroid Diseases
Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment
The intraoperative recognition of target structures, which need to be preserved or selectively removed, is of paramount importance during surgical procedures.
- Conditions
- Parathyroid Diseases, Thyroid Diseases, Liver Cancer, Liver Metastases
- Trial name
- iEXMachyna3 (NCT04589884)
- Testing
- Hyperspectral Imaging
- Where
- France
- Volunteers
- 112 people
- Sponsor
- IHU Strasbourg
Hepatocellular Carcinoma
Effects of Statin on Hepatocellular Carcinoma Recurrence After Liver Transplantation
This study aims to investigate whether statin therapy can help prevent recurrence of hepatocellular carcinoma (HCC) in transplant recipients who had liver transplantation for HCC.
- Trial name
- NCT03490461
- Testing
- Statin
- Where
- South Korea
- Volunteers
- 350 people
- Sponsor
- Yonsei University
Fibrolamellar Carcinoma, Fibrolamellar Liver Cancer
Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)
There is no effective standard treatment for fibrolamellar liver cancer that cannot be removed by surgery. The investigators want to find out what effects, good and/or bad, 3 drugs called letrozole, leuprolide and everolimus will…
- Trial name
- NCT01642186
- Testing
- everolimus, letrozole plus leuprolide, combination of everolimus, letrozole and leuprolide
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
- Trial name
- NCT03642561
- Testing
- radiotherapy ablation, transarterial chemoembolization(TACE)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Fudan University
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function
This phase I trial is studying the side effects and best dose of sorafenib in treating patients with metastatic or unresectable solid tumors, multiple myeloma, or non-Hodgkin's lymphoma with or without impaired liver or kidney…
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT00118170
- Testing
- sorafenib tosylate, pharmacological study
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor, Metastatic Solid Tumors
Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET
A phase 1/2, first-in-human, open-label study of the safety, tolerability, PK, and efficacy of the novel MET/CSF1R/SRC inhibitor TPX-0022 in adult subjects with advanced or metastatic NSCLC, Gastric Cancer, or solid tumors…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations
- Trial name
- SHIELD-1 (NCT03993873)
- Testing
- elzovantinib (TPX-0022)
- Where
- 24 sites in United States, France and 3 more
- Volunteers
- 95 people
- Sponsor
- Turning Point Therapeutics, Inc.
Hepatocellular Carcinoma, Liver Hypertrophy
Prospective Post Y90 Liver Hypertrophy
Patients undergoing Y90 radioembolization to will be followed prospectively with CT volumetry to determine post-Y90 rate of liver hypertrophy.
- Trial name
- NCT02783261
- Testing
- CT volumetric measurement after Y90 radioembolization
- Where
- Singapore
- Volunteers
- 25 people
- Sponsor
- Singapore General Hospital
Pancreas Neoplasm, Neuroendocrine Tumors
Portal Vein Resection in Pancreatic Neuroendocrine Tumours
The limited evidence on the value of portal vein resection in patients with borderline resectable and/or locally advanced PanNENs is an incentive to carry out a retrospective multicentre study amongst centres with specific…
- Trial name
- PVNET (NCT04336839)
- Testing
- Portal vein resection / reconstruction
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Royal Free Hospital NHS Foundation Trust
Hepatocellular Carcinoma
Radiofrequency Ablation Assisted Hepatectomy Versus Hepatectomy Alone for Advanced Hepatocellular Carcinoma
RFA has become a standard method in the treatment of small HCC(≤2 cm) due to its ease of use, safety, cost-effectiveness, and minimal invasiveness.
- Trial name
- NCT01713244
- Testing
- RFA assisted Hepatectomy, Hepatectomy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Southwest Hospital, China
Hepatocellular Carcinoma
Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma
This is a non-randomized, prospective, pilot, Multicenter Study of Drug-eluting bead transarterial chemoembolization (DEB-TACE) using Doxorubicin-Loaded Embozene® Tandem™ Microspheres to treat hepatocellular carcinoma (HCC).
- Trial name
- MIRACLE I (NCT01798134)
- Testing
- TANDEM™
- Where
- 7 sites in Germany
- Volunteers
- 25 people
- Sponsor
- Boston Scientific Corporation
Hepatocellular Carcinoma
Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC
This study will evaluate the role of everolimus in combination with local Transcatheter Arterial Chemoembolization (TACE) procedure in patients with localized unresectable Hepatocellular Carcinoma (HCC).
- Trial name
- TRACER (NCT01379521)
- Testing
- everolimus
- Where
- 5 sites in Hong Kong, Taiwan and 1 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Liver Cancer, Metastatic Cancer
Chemotherapy in Treating Patients With Unresectable Primary or Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of pyrazoloacridine in treating patients who have…
- Trial name
- NCT00003714
- Testing
- Pyrazoloacridine
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma
A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma
This is a prospective, multicenter, randomized, open-label phase 3 study evaluating the efficacy and safety of transarterial chemoembolization (TACE) combined with a triple oral cocktail regimen versus TACE combined with targeted…
- Trial name
- Cocktail-001 (NCT07309419)
- Testing
- Apatinib, Camrelizumab, TACE
- Volunteers
- 222 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
The standard treatment for hepatocellular carcinoma (HCC) is surgery, such as, by hepatic resection or liver transplantation, but less than 20% of HCC patients are suitable for surgery.
- Trial name
- NCT01850667
- Testing
- Stereotactic body radiotherapy
- Where
- 7 sites in South Korea
- Volunteers
- 74 people
- Sponsor
- Korea Cancer Center Hospital
Liver Cancer, Ablation Techniques
The Safety and Efficacy of Irreversible Electroporation for the Treatment of Perivascular Liver Cancers
Malignant liver tumors are among the most common cancers worldwide, with over 10,000 new cases reported annually in Taiwan. Despite the availability of various treatment options, the prognosis for primary hepatocellular carcinoma…
- Conditions
- Liver Cancer, Ablation Techniques, Radiology
- Trial name
- NCT07214363
- Testing
- Irreversible Electroporation Ablation Generator
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.